Larry Blandford, PharmD—Column Editor

Pharma Insights

What Changes When Medicine Goes Digital?

03/15/2018

Amanda Lever, BSc

Auralyn MacKenzie, BSc

Larry Blandford, PharmD—Column Editor

Health care has become increasingly digitalized, but until now drugs have escaped digitalization. Advancements in digital technologies are changing how we think about disease management and even disease treatment....

Health...

03/15/2018

Journal of Clinical Pathways

Pharma Insights

Are Formulary Exclusion Lists Aligned or Contrary to the Shift to Value-Base Care?

09/19/2017

Andrew Cournoyer, RPh, MBA

Larry Blandford, PharmD—Column Editor

The use of formulary exclusion lists continues to expand, with clear impacts to the perception and use of all related medications. Annual updates to these lists suggest a need for careful evaluation by benefit...

The...

09/19/2017

Journal of Clinical Pathways

Pharma Insights

How Health System and Payer Perception of Value May Determine the Promise of Gene Therapies

02/13/2017

Aura Mackenzie

Larry Blandford, PharmD—Column Editor

The launch of gene therapies is imminent. Much of the discussion has centered on the possible prices of these treatments rather than on their value and management. The value of different gene therapies is likely to...

The...

02/13/2017

Journal of Clinical Pathways

Pharma Insights

Creating Room to Show Value of New Products When Good Enough Treatments Exist

11/15/2016

Dan Renick, RPh

Larry Blandford, PharmD—Column Editor

Traditional markets have grown crowded with acceptable treatments for large patient populations, which can limit access for drugs in development for these therapeutic areas. Rather than taking a head-on approach to...

...

11/15/2016

Journal of Clinical Pathways

Pharma Insights

Formulary Exclusion Lists Create Challenges for Pharma and Payers Alike

10/12/2016

Andrew Cournoyer, RPh, MBA

Larry Blandford, PharmD—Column Editor

The use of formulary exclusion lists is expanding—and such lists are beginning to shape the market by further limiting available drugs for narrow therapeutic areas while reducing redundancy of options in broader...

The...

10/12/2016

Journal of Clinical Pathways

Corrigendum

Corrigendum: Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer`s Treatments?

08/02/2016

Rick Lifsitz, MBA

Larry Blandford, PharmD—Column Editor

In the June 2016 article, “Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer’s Treatments?"1 the author and column editor would like to clarify several points....

In the...

08/02/2016

Journal of Clinical Pathways

Pharma Insights

Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer`s Treatments?

06/20/2016

Rick Lifsitz, MBA

Larry Blandford, PharmD—Column Editor

The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...

The...

06/20/2016

Journal of Clinical Pathways